title: Linking cancer genome to proteome: NCI's investment into proteogenomics.
abstract: Advances in both targeted and unbiased MS-based proteomics are now at a mature stage for comprehensively and reproducibly characterizing a large part of the cancer proteome. These developments combined with the extensive genomic characterization of several cancer types by large-scale initiatives such as the International Cancer Genome Consortium and Cancer Genome Atlas Project have paved the way for proteogenomic analysis of omics datasets and integration methods. The advances serve as the basis for the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium and this article highlights its current work and future steps in the area of proteogenomics.
authors.affiliation: Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Robert C
authors.initials: RC
authors.lastname: Rivers
authors.forename: Christopher
authors.initials: C
authors.lastname: Kinsinger
authors.forename: Emily S
authors.initials: ES
authors.lastname: Boja
authors.forename: Tara
authors.initials: T
authors.lastname: Hiltke
authors.forename: Mehdi
authors.initials: M
authors.lastname: Mesri
authors.forename: Henry
authors.initials: H
authors.lastname: Rodriguez
mesh_terms: D000818:Animals; D023281:Genomics / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism*; D020543:Proteome / Q000235:genetics* / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*
chemical_list: D020543:Proteome
keywords: Bioinformatics; Cancer; Proteogenomics